SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2025

Commission file number: 001-35223

_______________________

BioLineRx Ltd.

(Translation of registrant’s name into English)

~~_______________________~~2 HaMa’ayan Street

~~2 HaMa’ayan Street~~ Modi’in 7177871, Israel

(Address of Principal Executive Offices)

_______________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

~~BioLineRx~~On ~~Ltd.~~May ~~(the “Registrant”) announces that it will hold an Annual Meeting of Shareholders on June 29~~27, 2025, atthe ~~3:00~~Registrant ~~p.m.~~issued ~~(Israel~~a ~~time),~~press atrelease ~~the~~announcing ~~Registrant’s~~its ~~office,~~financial ~~Modi’in~~results ~~Technology~~for ~~Park,~~the 2three ~~HaMa’ayan~~months ~~Street,~~ended ~~Modi’in~~March ~~7177871~~31, ~~Israel~~2025. The ~~Notice of Annual General Meeting and Proxy~~ ~~Statement,~~ Registrant ~~the~~is ~~related~~also ~~proxy~~publishing ~~card~~its ~~and~~unaudited ~~voting~~interim ~~instruction~~consolidated ~~form~~financial ~~for~~statements, ~~holders~~as ofwell ~~American~~as ~~Depositary~~its ~~Shares~~operating ~~are~~and ~~attached~~financial toreview, ~~this~~as ~~Report~~of onMarch ~~Form~~31, ~~6-K~~2025 asand ~~Exhibit~~for ~~99.1,~~the ~~Exhibit 99.2~~three ~~and~~months ~~Exhibit~~then 99ended.3, ~~respectively,~~Attached ~~and~~hereto ~~incorporated~~are ~~herein~~the byfollowing ~~reference.~~exhibits:

Exhibit No.
99.1	BioLineRx Ltd. Notice and Proxy Statement for the Annual Geneal Meeting of Shareholders to be held on June 29, 2025
99.2	Form of Proxy Card
99.3	Form of Voting Instruction Form

Exhibit 1: Registrant’s press release dated May 27, 2025;

~~This~~Exhibit ~~Form~~2: ~~6-K,~~Registrant’s ~~including~~condensed ~~all~~consolidated ~~exhibits~~interim financial ~~hereto,~~statements isas ~~hereby~~of ~~incorporated~~March by31, ~~reference~~2025 ~~into~~and ~~all~~for ~~effective registration statements filed by~~ the ~~registrant~~three ~~under~~months ~~the~~then ~~Securities~~ended; ~~Act of 1933.~~and

~~SIGNATURES~~Exhibit 3: Registrant’s operating and financial review as of March 31, 2025 and for the three months then ended.

This Form 6-K, the text under the heading “Financial Results for the Quarter Ended March 31, 2025” in Exhibit 1, Exhibit 2 and Exhibit 3 are hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BioLineRx Ltd.

	By:	/s/ Philip A. Serlin
		Philip A. Serlin
		Chief Executive Officer

Dated: May 2327, 2025

Filing Compare · BioLineRx Ltd.